Please assess the completion status of the following clinical trial:

Trial Title: Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* metastatic renal cell carcinoma (kidney cancer) with clear cell component~* no prior systemic therapy (including no prior adjuvant or neoadjuvant)~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1~* Blood Pressure \< or = 140/90mmHg~Exclusion Criteria:~* brain/CNS metastasis~* using more than 2 blood pressure medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Randomized arm
- B (Type: OTHER): Randomized arm
- C (Type: OTHER): Non-randomized arm

Based on this trial design, predict the completion outcome and termination type (if applicable).